In tumors from HNSCC patients, those with cyclin D1-positive tumors had a poor prognosis associated with lymph node metastasis, recurrence and shorter patient survival compared with cyclin D1-negative tumors, indicating a potential use for these markers in predicting the clinical outcome of HNSCC patients [12], [13]. The gene discussed is CCND1; the disease is metastatic malignant neoplasm in the lymph nodes.